MENA Forum – Medical and Market Access Pharma Summit 2026

Dubai, UAE 28 - 29 April 2026

The MENA Forum – Medical & Market Access Pharma Summit 2026 brings together global and regional leaders to shape the future of evidence generation, pricing, and access in the Middle East and North Africa. Over two days, senior executives, regulators, researchers, and innovators will explore how real-world evidence (RWE), digital health, and value-based models can transform patient outcomes across diverse healthcare systems. This high-level summit will address the convergence of global best practices with MENA-specific needs, ensuring that payers, policymakers, and industry stakeholders can align on sustainable and patient-centered solutions. Through insightful sessions, case studies, and panel discussions, attendees will gain actionable strategies for overcoming data gaps, driving regulatory harmonization, and implementing innovative reimbursement frameworks. This is where the future of evidence and access in MENA begins.

Topic highlights

– GCC HTA Convergence: Cross-border dossier recognition frameworks for reimbursement by 2030.
– Interoperable RWD Infrastructure: EMR, claims, registries, and ePRO integration with robust governance.
– RWE for Market Access: Designing pragmatic trials and ensuring reliability, validity, and payer relevance.
– Digital Health & Data Integration: Leveraging EHRs, AI, and big data for evidence generation.
– Collaborations Across Stakeholders: Academia–industry–regulator partnerships for high-quality evidence.
– Patient-Centered Evidence: Engaging patients in design, dissemination, and culturally relevant outcomes.
– Pricing & Reimbursement Models: Innovative agreements balancing affordability and sustainability.
– Value-Based Healthcare: Transitioning from volume to value with outcomes that matter in MENA.
– Future of Evidence & Market Access: Predictive analytics, digital transformation, and sustainable financing.

Meet the experts

The summit convenes an exceptional lineup of board members, C-level executives, VPs, and global directors from the pharmaceutical, biotech, and healthcare ecosystem. Attendees will engage directly with:

Rima El Khatib

Head of Market Access and Government Affairs

Menarini Group

Topic: Evolving Market Access Pathways in MENA

· Current HTA developments across UAE, KSA, Egypt, etc.
· Regional payer requirements and evidence expectations.
· Opportunities for harmonization across markets.

Khaled Fahim

Medical Director Gulf

Merck Group

Omneya Mohamed

Head of Health Economics, Market Access and Reimbursement (HEMAR) – Middle East

Baxter International Inc.

Hany Salah

Intercontinental Medical Director – Rheumatology

AbbVie

Amir A. Mohseni

Senior Director, Medical Affairs

Eli Lilly & Company

Jihen Toumi

Head of Medical Affairs Innovative Medicines Gulf

Novartis Gulf

Diederik Kok

Head of GCC

Biogen

Dr. Yehia Nabil, MD

Medical Affairs Director & Consultant of Internal Medicine

Gilead Sciences – Middle East

Amr Nasrallah

Market Access Director

Johnson & Johnson

Maya Jarkas

Country Medical Head East Gulf and Levant

Takeda

Key takeaways and benefits

Gain clarity on HTA convergence and reimbursement frameworks across the GCC and wider MENA region.

Understand how to operationalize RWE for regulatory and payer decision-making.

Learn innovative approaches to pricing, reimbursement, and value-based healthcare.

Discover how digital health, AI, and big data are transforming evidence generation.

Explore patient-centered strategies to improve engagement and evidence relevance.

Access exclusive case studies and best practices from MENA and global pioneers.

Develop a future-ready market access roadmap with predictive insights and sustainable models.

Benchmark your strategies against regional and global standards.

Expand your network with the most influential leaders in MENA pharma and healthcare.